Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1

26 Aug 2021

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacillus and Francisella bacterial research
Share to SARS-CoV-2 and COVID-19 Research
Share to vaccines and immunoinformatics approaches

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 34481699
DOI: 10.1016/j.vaccine.2021.08.081

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1PMID 34481699Read ↗

SARS-COV-2 Recombinant Receptor-Binding-Domain (RBD) Induces Neutralising Antibodies Against Variant Strains of SARS-CoV-2 and SARS-CoV-1Semantic proximity Read ↗

Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodiesSemantic proximity Read ↗

A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitopeSemantic proximity Read ↗

An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19Semantic proximity Read ↗

Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect In Vivo in a Mouse Model in a Neutralization-Dependent MannerSemantic proximity Read ↗

SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escapeSemantic proximity Read ↗

Antibodies and Vaccines Target RBD of SARS-CoV-2Semantic proximity Read ↗

Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2Semantic proximity Read ↗

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strainsSemantic proximity Read ↗

A rapid and efficient screening system for neutralizing antibodies and its application for the discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBDSemantic proximity Read ↗

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralizationSemantic proximity Read ↗

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.